Preferred name | reserpine |
Trivial Name | (-)-Reserpine |
Short Description | methyl reserpate 3,4,5-trimethoxybenzoic acid ester |
Formula | C33 H40 N2 O9 |
CAS Number | 50-55-5 |
Deleted CAS Number | 1407-38-1 |
ECHA Number | 200-047-9 |
FDA UNII | 8B1QWR724A |
Nikkaji Number | J1.359E |
Beilstein Number | 0102014 |
MDL | MFCD00005091 |
xLogP3-AA | 4.00 (est) |
Bio Activity Summary | External link |
NMR Predictor | External link |
Synonyms |
|
Google Scholar | Start search |
Google Books | Start search |
Google Patents | Start search |
Perfumer & Flavorists | Start search |
EU Patents | Start search |
PubMeb | Start search |
NCBI | Start search |
methyl(1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate | |
NIST Chemistry WebBook: | Search Inchi |
Pubchem (cid): | 5770 |
Pubchem (sid): | 134971500 |
(IUPAC): | Atomic Weights of the Elements 2011 (pdf) |
Videos: | The Periodic Table of Videos |
tgsc: | Atomic Weights use for this web site |
(IUPAC): | Periodic Table of the Elements |
CHEBI: | View |
CHEMBL: | View |
KEGG (GenomeNet): | C06539 |
HMDB (The Human Metabolome Database): | Search |
Export Tariff Code: | 2939.90.5000 |
MedlinePlusSupp: | View |
ChemSpider: | View |
Wikipedia: | View |
Formulations/Preparations: •reserpine (sandril, serpasil, others) is available in tablets that contain 0.1, 0.25 or 1.0 mg or in capsules that contain 0.5 mg •dosage forms- extended-release capsules: 0.5 mg. elixir: 0.2 mg4 ml; injection: 5 mg2 ml, and 25 mg10 ml; tablets; 0.1, 0.25, 0.5, and 1 mg •reserpine combinations: oral tablets: 0.1 mg with hydralazine hydrochloride 25 mg: serpasil, apresoline, hydrochloride #1 (with tartrazine) (ciba); 0.1 mg with hydralazine hydrochloride 25 mg and hydrochlorothiazide 15 mg: cherpas (kay), hhr (geneva generics, schein, towne), hydroserpine plus (zenith), rezide (edward), ser-a-gen (goldline) ser-ap-es (ciba), serathide (interstate), serpazide (major), tri-hydroserpine (rugby), unipres (reid-rowell). •reserpine combinations: oral tablets: 0.1 mg with hydrochlorothiazide 25 mg: serpasil, esidrix (with tartazine) (ciba); 0.1 mg with hydrochlorothiazide 50 mg: serpasil, esidrix #2 (with tartazine) (ciba), 0.1 mg with methyclothiazide 2.5 mg: diutensen-r (wallace); 0.1 mg with trichloromethiazide: 2 mg: metatensin #2 (with tartrazine) (merrell dow); 0.1 mg with trichlormethiazide 4 mg: diurese-r (american urologicals), metatensin #4 (merrell dow), naquival (with tatazine) (schering), trichlormethanizide with resperpine tablets (bolar, moore); trichlortensin (rugby); 0.125 mg with chlorothiazide 250 mg: chloroserp-250 (quality generics), chloroserpine-250 (rugby, schein), diupres 250. •reserpine combinations: oral tablets: 0.125 mg with chlorothiazide 500 mg: chloroserp-500 (quality generics), chloroserpine-500 (rugby, schein), diupres 500 (msd); 0.125 mg with chlorthalidone 25 mg: demi-regroton (usv); 0.125 mg with hydrochlorothiazide 25 mg: hydropres 25 (msd), hydro-reserpine-25 (interstate), hydroserp (bioline, quality generics), hydroserpine #1 (goldline, rugby, schein, zenith), hydrosine 25 mg (major), mallopress (mallard); 0.125 mg with hydrochlorothiazide 50 mg: hydropres 50 (msd), hydro-reserpine-50 (interstate), hydroserp (bioline, quality generics), hydroserpalan (lannett), hydroserpine #2 (goldline, rugby, schein, zenith), hydrosine 50 mg (major), hydrotensin-50 (mayrand). •reserpine combinations: oral tablets: 0.125 mg with hydroflumethiazide 25 mg: hydro-fluserpine #1 (schein), hydropine (rugby), salazide-demi (major), salutensin-demi (bristol); 0.125 mg with quinethazone 50 mg: hydromox-r (lederle); 0.2 mg with hydralazine hydrochloride 50 mg: serpasil-apresoline hydrochloride #2 (with tartrazine) (ciba); 0.25 mg with chlorthalidone 50 mg: regroton (usv); 0.25 mg with polythiazide 2 mg: renese-r (pfizer). •oral tablets: serpalan (lilly) 0.1 and 0.25 mg; serpasil (lannett) 0.1 and 0.25 mg; serpate (vale) 0.1 and 0.25 mg; 1 mg reserpine tablets (towne) •reserpine elixir: an elixir containing reserpine and alcohol 11 to 13%. •reserpine injection: a sterile solution of resperine in water for injections, prepared with the aid of a suitable acid. •seominal: tablets each containing reserpine 200 ug, phenobarbitone 10 mg, and theobromine 325 mg. |
Material listed in food chemical codex | No |
Molecular weight | 608.68859863281 |
Flash Point TCC Value | 377.2 °C TCC |
logP (o/w) | 4.05 est |
Solubility | |
water, 73 mg/L @ 30 °C (exp) | Yes |
water, 2.084 mg/L @ 25 °C (est) | Yes |
Preferred SDS: View | |
Hazards identification | |
Classification of the substance or mixture | |
GHS Classification in accordance with 29 CFR 1910 (OSHA HCS) | |
None found. | |
GHS Label elements, including precautionary statements | |
Pictogram | |
Hazard statement(s) | |
None found. | |
Precautionary statement(s) | |
None found. | |
Oral/Parenteral Toxicity: | |
oral-bird - wild LD50 100 mg/kg Toxicology and Applied Pharmacology. Vol. 21, Pg. 315, 1972. intravenous-dog LD50 500 ug/kg "Drug Dosages in Laboratory Animals - A Handbook," Rev. ed., Barnes, C.D., and L.G. Eltherington, Berkeley, Univ. of California Press, 1973Vol. -, Pg. 234, 1973. intravenous-guinea pig LDLo 16 mg/kg Arzneimittel-Forschung. Drug Research. Vol. 23, Pg. 600, 1973. intraperitoneal-mouse LD50 5 mg/kg European Journal of Medicinal Chemistry--Chimie Therapeutique. Vol. 10, Pg. 519, 1975. intravenous-mouse LD50 21 mg/kg GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) BEHAVIORAL: CHANGES IN MOTOR ACTIVITY (SPECIFIC ASSAY) Arzneimittel-Forschung. Drug Research. Vol. 14, Pg. 1040, 1964. oral-mouse LD50 > 50 mg/kg Drugs in Japan Vol. -, Pg. 1453, 1995. intraperitoneal-rabbit LD50 7 mg/kg Journal of Drug Research. Vol. 6(3), Pg. 19, 1974. intravenous-rabbit LD50 15 mg/kg "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 111, 1972. intraperitoneal-rat LD50 44 mg/kg BRAIN AND COVERINGS: RECORDINGS FROM SPECIFIC AREAS OF CNS Archives Internationales de Pharmacodynamie et de Therapie. Vol. 110, Pg. 20, 1957. intravenous-rat LD50 15 mg/kg "Psychotropic Drugs and Related Compounds," 2nd ed., Usdin, E., and D.H. Efron, Washington, DC, 1972Vol. -, Pg. 111, 1972. oral-rat LD50 420 mg/kg BEHAVIORAL: ANTIPSYCHOTIC Pesticide Science. Vol. 11, Pg. 555, 1980. | |
Dermal Toxicity: | |
subcutaneous-guinea pig LD50 65 mg/kg Archives Internationales de Pharmacodynamie et de Therapie. Vol. 137, Pg. 375, 1962. subcutaneous-mouse LD50 5610 ug/kg Drugs in Japan Vol. -, Pg. 1453, 1995. subcutaneous-rat LD50 25 mg/kg Nippon Yakurigaku Zasshi. Japanese Journal of Pharmacology. Vol. 56, Pg. 377, 1960. | |
Inhalation Toxicity: | |
Not determined |
Category: | |||
pharmaceuticals / chemical synthisis | |||
Recommendation for reserpine usage levels up to: | |||
not for fragrance use. | |||
Recommendation for reserpine flavor usage levels up to: | |||
not for flavor use. |
EPI System: View |
ClinicalTrials.gov:search |
Daily Med:search |
Chemical Carcinogenesis Research Information System:Search |
AIDS Citations:Search |
Cancer Citations:Search |
Toxicology Citations:Search |
Carcinogenic Potency Database:Search |
EPA GENetic TOXicology:Search |
EPA Substance Registry Services (TSCA):50-55-5 |
EPA ACToR:Toxicology Data |
EPA Substance Registry Services (SRS):Registry |
Laboratory Chemical Safety Summary :5770 |
National Institute of Allergy and Infectious Diseases:Data |
WGK Germany:3 |
methyl(1R,15S,17R,18R,19S,20S)-6,18-dimethoxy-17-(3,4,5-trimethoxybenzoyl)oxy-1,3,11,12,14,15,16,17,18,19,20,21-dodecahydroyohimban-19-carboxylate |
Chemidplus:0000050555 |
EPA/NOAA CAMEO:hazardous materials |
RTECS:ZG0350000 for cas# 50-55-5 |